| Literature DB >> 36093399 |
Wei Yang1,2,3,4, Yong Liang5, Yuanyuan Zheng1,2,3,4, Haitao Luo1,2,3,4, Xiaofei Yang1,2,3,4, Furong Li1,2,3,4.
Abstract
ALDH+ H1975 lung adenocarcinoma stem cells (LSCs) are a rare cell population identified in lung adenocarcinoma (LUAD). LSCs can self-renew, drive tumor initiation, growth, metastasis, and recurrence and are also the predominant cause of poor prognosis due to their intrinsic resistance to drugs and chemotherapy. Consequently, LSCs are a promising target for LUAD therapy. Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), exert many significant regulatory functions in the pathogenesis of human cancers, showing the necessity for a comprehensive understanding of the mechanisms that underlie lung carcinogenesis. Nonetheless, research on many known transcripts and messenger RNAs (mRNAs) has already generated new information. Unknown biomarkers in ncRNAs and systematic and comprehensive interrelation with unknown ncRNAs and mRNAs may provide further insights into the biology of LUAD. Herein, a set of novel ncRNAs that include miRNAs, lncRNAs, and circRNAs were identified, and differentially expressed patterns of ncRNAs and mRNAs in LSCs and ALDH-H1975 LUAD tumor cells (LTCs) were obtained using stringent bioinformatics pipelines. Through a meta-analysis of the identified landscapes, novel competitive endogenous RNA (ceRNA) networks were constructed to reveal the potential molecular mechanisms that regulate the hallmarks of LSCs and LTCs. This study presents a summary of novel ncRNAs and the fundamental roles of differentially expressed ncRNAs implicated in the activity of LSCs and LTCs. In addition, the study also provides a comprehensive resource for the future identification of diagnostic, therapeutic, and prognostic biomarkers in LUAD.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36093399 PMCID: PMC9453044 DOI: 10.1155/2022/9545609
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1Distribution of novel and known lncRNAs/circRNAs and DE lncRNAs/circRNAs, mRNAs. (a) Sample correlation; (b) transcript classes; and (c) in silico pipeline used for the identification of novel lncRNAs. The purple number next to the bar is the remaining count of lncRNAs after filtering each step; (d) bioinformatics pipeline used for the identification of circRNAs; (e) FPKM density of all transcripts; (f) composition of known and novel lncRNAs; (g) violin plot of transcripts between lncRNA and mRNA and group LTCs and group LSCs; (h) counts of lncRNA and circRNA; (i) composition of circRNAs; and (j) Venn diagram showing predicted circRNAs in LTCs and LSCs, respectively.
Figure 2Distribution of novel and known miRNA and DE miRNAs. (a) small RNA (sRNA) category ratio; (b) sample correlation; (c) miRNA percentage from the miRbase database of known miRNAs; (d) first base bias and position base bias on known miRNA; (e) TMP density of all miRNAs; (f) Venn diagram on predicted miRNA in LSCs and LTCs; and (g) volcano plot of DE miRNAs.
Figure 3KEGG pathway analysis and GO cluster analysis. (a) Common pathway found in both upregulated gene sets and downregulated gene sets; (b) specific Kegg pathways in downregulated gene sets; (c) specific KEGG pathways in upregulated gene sets; (d) clusters of GO terms in downregulated gene sets; and (e) clusters of GO terms in downregulated gene sets.
Figure 4Constructed ceRNA networks. The left subnetwork consisted of upregulated miRNAs, downregulated mRNAs, and downregulated lncRNA/circRNAs; the right subnetwork consisted of downregulated miRNAs, upregulated mRNAs, and upregulated lncRNA/circRNAs. Green arrow, lncRNA/circRNA; orange circle, mRNA; purple rhombus, miRNAs; combination of brown line and semicircle, inhibition or degradation, respectively; light green line or arrow, promotion. A large or small shape (green arrow/orange circle/purple rhombus) indicates upregulation or downregulation, respectively.
Figure 5GO analysis and MCODE analysis. (a) GO analysis of upregulated gene sets comprising the ceRNA networks; (b) GO analysis of downregulated gene sets comprising the ceRNA networks; (c) Four main subnetworks; (d) Heatmap of 11 transcripts in the four subnetworks.
Figure 6Survival analysis of patients with LUAD. Overall survival analysis stratifying patients by median expression of (a) TUFT1 and (b) LNC_00236; (c) relapse-free survival analysis of patients stratified by LNC_00236 expression; and (d) LNC_00236 expression atlas in tumor and normal tissue.